Medico Intercontinental Ltd (539938)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Medico Intercontinental's revenue was ₹20.7 Cr (-3.0% year on year, -7.9% on the previous quarter), and net profit ₹-4.0 Cr (a bigger loss than a year earlier); the operating margin was -3.3%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹20.7 | -3.0% | -7.9% |
| Operating profit | ₹-0.7 | to loss | to loss |
| Net profit | ₹-4.0 | loss widened | loss widened |
| EPS (₹) | -1.45 | loss widened | loss widened |
| Operating margin | -3.3% | — | — |
📢 Recent Corporate Announcements
Medico Intercontinental Limited has released its Annual Report for FY25-26 and convened its 42nd Annual General Meeting for September 30, 2026. Key special resolutions include approval of related-party transactions for FY 2026-27 with Oxford Pharma (up to ₹25 crore) and LYF Distributor (up to ₹6 crore). The management message also highlighted the strategic acquisition of a 51% stake in Calborn Lifescience, noting it is currently loss-making with an expected gestation period of 3 to 4 years.
- 42nd AGM scheduled for September 30, 2026; e-voting window from September 27 to September 29, 2026 with record cut-off on September 23, 2026
- Shareholder approval sought for related party transactions up to ₹25 crore with Oxford Pharma for FY 2026-27
- Approval sought for related party transactions up to ₹6 crore with LYF Distributor for FY 2026-27
- Management noted a 51% stake acquisition in Calborn Lifescience Private Limited to expand into Vitamin D3 manufacturing
Medico Intercontinental reported consolidated revenue from operations of Rs 20.71 Cr for Q1 ended June 30, 2026, down 3.0% YoY from Rs 21.35 Cr and down 6.6% QoQ from Rs 22.19 Cr. Consolidated net loss expanded significantly to Rs 4.04 Cr compared to a net loss of Rs 2.49 Cr in Q1 FY26 and Rs 2.33 Cr in Q4 FY26. Net loss attributable to owners was Rs 1.45 Cr, translating to a diluted EPS of Rs -1.45. Standalone operations remained marginally profitable with a PAT of Rs 0.61 Cr on revenue of Rs 14.33 Cr.
- Consolidated revenue from operations decreased 3.0% YoY to Rs 20.71 Cr (vs Rs 21.35 Cr in Q1 FY26)
- Consolidated net loss widened to Rs 4.04 Cr compared to a loss of Rs 2.49 Cr in Q1 FY26 and Rs 2.33 Cr in Q4 FY26
- Consolidated loss before tax expanded to Rs 3.68 Cr from Rs 2.04 Cr in the year-ago period
- Standalone PAT stood at Rs 60.76 Lakhs on revenue of Rs 14.33 Cr, compared to Rs 55.60 Lakhs PAT in Q1 FY26
- Annual General Meeting (AGM) scheduled for September 30, 2026, with cut-off date set to September 23, 2026
Medico Intercontinental reported consolidated revenue from operations of ₹20.71 Cr (₹2,071.15 lakhs) for the quarter ended June 30, 2026, down 3.0% YoY from ₹21.35 Cr in Q1 FY26. Consolidated net loss widened to ₹4.04 Cr compared to a loss of ₹2.49 Cr in Q1 FY26, burdened by finance costs of ₹1.91 Cr and operating expenses. On a standalone basis, the company posted a net profit of ₹0.61 Cr on revenue of ₹14.33 Cr. The company's 42nd Annual General Meeting is scheduled for September 30, 2026.
- Consolidated revenue from operations decreased 3.0% YoY to ₹20.71 Cr vs ₹21.35 Cr in Q1 FY26
- Consolidated net loss expanded to ₹4.04 Cr vs a loss of ₹2.49 Cr in the corresponding prior-year quarter
- Standalone revenue stood at ₹14.33 Cr with PAT of ₹0.61 Cr and basic EPS of ₹0.61
- Consolidated finance costs rose to ₹1.91 Cr against ₹1.36 Cr in Q1 FY26
- Annual General Meeting set for September 30, 2026, with cut-off date on September 23, 2026
Medico Intercontinental Ltd has scheduled a board meeting on August 14, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is currently navigating a difficult financial period, having reported a net loss of Rs 11 crore in FY26 compared to a profit of Rs 5 crore in FY25. With a debt-to-equity ratio of 1.43 and a market cap of Rs 93 crore, the upcoming results are critical to assess if the company can reverse its trend of four consecutive loss-making quarters. The trading window for insiders has been closed since June 30, 2026.
- Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results.
- Company reported a net loss of Rs 11 crore for the full year FY26.
- Trading window has been closed since June 30, 2026, for designated persons.
- Revenue for the most recent quarter (Mar 2026) was Rs 22.49 crore with a net loss of Rs 2.33 crore.
- Total debt stands at Rs 67 crore against a net worth of Rs 47 crore.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
